Apogee Therapeutics

Update in progress

APGE (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company developing novel biologics for inflammatory and immunology conditions in the United States, including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline includes Zumilokibart (APG777), an SQ extended-half-life mAb in phase 2 for atopic dermatitis and phase 1 for asthma and EoE; APG279 (phase 1) for atopic dermatitis; APG273 (phase 1) for asthma/COPD; and APG808 (SQ anti-IL-4Rα) for Type 2 diseases. Based in Waltham, MA, founded 2022.

Company score

Sentiment: 0.06; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.32; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.08; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive